Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Parkinson's Disease

  Free Subscription


Articles published in Exp Neurol

Retrieve available abstracts of 57 articles:
HTML format
Text format



Single Articles


    August 2018
  1. CHENG S, Tereshchenko J, Zimmer V, Vachey G, et al
    Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector.
    Exp Neurol. 2018;309:79-90.
    PubMed     Text format     Abstract available


  2. WU S, Lei L, Song Y, Liu M, et al
    Mutation of hop-1 and pink-1 attenuates vulnerability of neurotoxicity in C. elegans: the role of mitochondria-associated membrane proteins in Parkinsonism.
    Exp Neurol. 2018;309:67-78.
    PubMed     Text format     Abstract available


    July 2018
  3. HOSSAIN MM, Weig B, Reuhl K, Gearing M, et al
    The anti-parkinsonian drug zonisamide reduces neuroinflammation: Role of microglial Nav 1.6.
    Exp Neurol. 2018;308:111-119.
    PubMed     Text format     Abstract available


    June 2018
  4. ZHANG Z, Shen Y, Luo H, Zhang F, et al
    MANF protects dopamine neurons and locomotion defects from a human alpha-synuclein induced Parkinson's disease model in C. elegans by regulating ER stress and autophagy pathways.
    Exp Neurol. 2018 Jun 27. pii: S0014-4886(18)30206.
    PubMed     Text format     Abstract available


    May 2018
  5. DU TT, Chen YC, Lu YQ, Meng FG, et al
    Subthalamic nucleus deep brain stimulation protects neurons by activating autophagy via PP2A inactivation in a rat model of Parkinson's disease.
    Exp Neurol. 2018 May 21. pii: S0014-4886(18)30127.
    PubMed     Text format     Abstract available


    April 2018
  6. EKIMOVA IV, Plaksina DV, Pastukhov YF, Lapshina KV, et al
    New HSF1 inducer as a therapeutic agent in a rodent model of Parkinson's disease.
    Exp Neurol. 2018 Apr 25. pii: S0014-4886(18)30099.
    PubMed     Text format     Abstract available


    March 2018
  7. ROUILLARD C, Baillargeon J, Paquet B, St-Hilaire M, et al
    Genetic disruption of the nuclear receptor Nur77 (Nr4a1) in rat reduces dopamine cell loss and l-Dopa-induced dyskinesia in experimental Parkinson's disease.
    Exp Neurol. 2018 Mar 9. pii: S0014-4886(18)30070.
    PubMed     Text format     Abstract available


    February 2018
  8. SUN X, Aime P, Dai D, Ramalingam N, et al
    Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease.
    Exp Neurol. 2018 Feb 9. pii: S0014-4886(18)30022.
    PubMed     Text format     Abstract available


    January 2018
  9. REN M, Guo Y, Wei X, Yan S, et al
    TREM2 overexpression attenuates neuroinflammation and protects dopaminergic neurons in experimental models of Parkinson's disease.
    Exp Neurol. 2018;302:205-213.
    PubMed     Text format     Abstract available


  10. YU Q, Huang Q, Du X, Xu S, et al
    Early activation of Egr-1 promotes neuroinflammation and dopaminergic neurodegeneration in an experimental model of Parkinson's disease.
    Exp Neurol. 2018 Jan 11. pii: S0014-4886(18)30016.
    PubMed     Text format     Abstract available


  11. LIMA JC, Oliveira LM, Botelho MT, Moreira TS, et al
    The involvement of the pathway connecting the substantia nigra, the periaqueductal gray matter and the retrotrapezoid nucleus in breathing control in a rat model of Parkinson's disease.
    Exp Neurol. 2018 Jan 3. pii: S0014-4886(18)30003.
    PubMed     Text format     Abstract available


    December 2017
  12. GALATI S, Song W, Orban G, Luft AR, et al
    Cortical slow wave activity correlates with striatal synaptic strength in normal but not in Parkinsonian rats.
    Exp Neurol. 2017;301.
    PubMed     Text format     Abstract available


  13. CENCI MA, Olanow CW
    Translating scientific advances into disease-modifying therapies for Parkinson's Disease.
    Exp Neurol. 2017;298.
    PubMed     Text format    


  14. BRUNDIN P, Dave KD, Kordower JH
    Therapeutic approaches to target alpha-synuclein pathology.
    Exp Neurol. 2017;298.
    PubMed     Text format     Abstract available


  15. SMITH L, Mullin S, Schapira AHV
    Insights into the structural biology of Gaucher disease.
    Exp Neurol. 2017;298.
    PubMed     Text format     Abstract available


  16. OLANOW CW, Kieburtz K, Katz R
    Clinical approaches to the development of a neuroprotective therapy for PD.
    Exp Neurol. 2017;298.
    PubMed     Text format     Abstract available


    November 2017
  17. BONATO JM, Bassani TB, Milani H, Vital MA, et al
    Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats.
    Exp Neurol. 2017 Nov 18. pii: S0014-4886(17)30323.
    PubMed     Text format     Abstract available


  18. HARMS AS, Thome AD, Yan Z, Schonhoff AM, et al
    Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease.
    Exp Neurol. 2017;300:179-187.
    PubMed     Text format     Abstract available


  19. WANG YY, Wang Y, Jiang HF, Liu JH, et al
    Impaired glutamatergic projection from the motor cortex to the subthalamic nucleus in 6-hydroxydopamine-lesioned hemi-parkinsonian rats.
    Exp Neurol. 2017;300:135-148.
    PubMed     Text format     Abstract available


  20. CHAO H, Liu Y, Fu X, Xu X, et al
    Lowered iPLA2gamma activity causes increased mitochondrial lipid peroxidation and mitochondrial dysfunction in a rotenone-induced model of Parkinson's disease.
    Exp Neurol. 2017 Nov 2. pii: S0014-4886(17)30291.
    PubMed     Text format     Abstract available


    October 2017
  21. FRANCARDO V, Schmitz Y, Sulzer D, Angela Cenci M, et al
    Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease.
    Exp Neurol. 2017 Oct 5. pii: S0014-4886(17)30243.
    PubMed     Text format     Abstract available


  22. BLESA J, Trigo-Damas I, Dileone M, Del Rey NL, et al
    Compensatory mechanisms in Parkinson's disease: Circuits adaptations and role in disease modification.
    Exp Neurol. 2017 Oct 4. pii: S0014-4886(17)30244.
    PubMed     Text format     Abstract available


    September 2017
  23. KUHN J, Haumesser JK, Beck MH, Altschuler J, et al
    Differential effects of levodopa and apomorphine on neuronal population oscillations in the cortico-basal ganglia loop circuit in vivo in experimental parkinsonism.
    Exp Neurol. 2017 Sep 8. pii: S0014-4886(17)30235.
    PubMed     Text format     Abstract available


    August 2017
  24. JAMES SURMEIER D, Halliday GM, Simuni T
    Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease.
    Exp Neurol. 2017 Aug 2. pii: S0014-4886(17)30206.
    PubMed     Text format     Abstract available


    July 2017
  25. WEST AB
    Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.
    Exp Neurol. 2017 Jul 29. pii: S0014-4886(17)30203.
    PubMed     Text format     Abstract available


  26. KO WKD, Bezard E
    Experimental animal models of Parkinson's disease: A transition from assessing symptomatology to alpha-synuclein targeted disease modification.
    Exp Neurol. 2017 Jul 29. pii: S0014-4886(17)30202.
    PubMed     Text format     Abstract available


  27. FISCHER P, Pogosyan A, Cheeran B, Green AL, et al
    Subthalamic nucleus beta and gamma activity is modulated depending on the level of imagined grip force.
    Exp Neurol. 2017;293:53-61.
    PubMed     Text format     Abstract available


    June 2017
  28. CROTTY GF, Ascherio A, Schwarzschild MA
    Targeting urate to reduce oxidative stress in Parkinson disease.
    Exp Neurol. 2017 Jun 13. pii: S0014-4886(17)30157.
    PubMed     Text format     Abstract available


  29. MEADOWS SM, Chambers NE, Conti MM, Bossert SC, et al
    Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia.
    Exp Neurol. 2017;292:168-178.
    PubMed     Text format     Abstract available


    May 2017
  30. MOREIRA S, Fonseca I, Nunes MJ, Rosa A, et al
    Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson's disease.
    Exp Neurol. 2017 May 25. pii: S0014-4886(17)30126.
    PubMed     Text format     Abstract available


  31. LAZARO DF, Pavlou MAS, Outeiro TF
    Cellular models as tools for the study of the role of alpha-synuclein in Parkinson's disease.
    Exp Neurol. 2017 May 16. pii: S0014-4886(17)30124.
    PubMed     Text format     Abstract available


    April 2017
  32. SCOTT L, Dawson VL, Dawson TM
    Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes.
    Exp Neurol. 2017 Apr 23. pii: S0014-4886(17)30102.
    PubMed     Text format     Abstract available


  33. ALAM M, Rumpel R, Jin X, von Wrangel C, et al
    Altered somatosensory cortex neuronal activity in a rat model of Parkinson's disease and levodopa-induced dyskinesias.
    Exp Neurol. 2017 Apr 23. pii: S0014-4886(17)30101.
    PubMed     Text format     Abstract available


  34. OLIVEIRA LM, Tuppy M, Moreira TS, Takakura AC, et al
    Role of the locus coeruleus catecholaminergic neurons in the chemosensory control of breathing in a Parkinson's disease model.
    Exp Neurol. 2017;293:172-180.
    PubMed     Text format     Abstract available


    March 2017
  35. BIMPISIDIS Z, M Oberg C, Maslava N, Cenci MA, et al
    Differential effects of gaseous versus injectable anesthetics on changes in regional cerebral blood flow and metabolism induced by l-DOPA in a rat model of Parkinson's disease.
    Exp Neurol. 2017 Mar 8. pii: S0014-4886(17)30066.
    PubMed     Text format     Abstract available


    February 2017
  36. MONNOT C, Zhang X, Nikkhou-Aski S, Damberg P, et al
    Asymmetric dopaminergic degeneration and levodopa alter functional corticostriatal connectivity bilaterally in experimental parkinsonism.
    Exp Neurol. 2017 Feb 18. pii: S0014-4886(17)30048.
    PubMed     Text format     Abstract available


    January 2017
  37. FRAU R, Savoia P, Fanni S, Fiorentini C, et al
    The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Exp Neurol. 2017;291:1-7.
    PubMed     Text format     Abstract available


  38. HAO F, Yang C, Chen SS, Wang YY, et al
    Long-Term Protective Effects of AAV9-Mesencephalic Astrocyte-Derived Neurotrophic Factor Gene Transfer in Parkinsonian Rats.
    Exp Neurol. 2017 Jan 25. pii: S0014-4886(17)30016.
    PubMed     Text format     Abstract available


  39. FJODOROVA M, Torres EM, Dunnett SB
    Transplantation site influences the phenotypic differentiation of dopamine neurons in ventral mesencephalic grafts in Parkinsonian rats.
    Exp Neurol. 2017 Jan 25. pii: S0014-4886(17)30019.
    PubMed     Text format     Abstract available


    December 2016
  40. BENTEA E, Van Liefferinge J, Verbruggen L, Martens K, et al
    Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system xc.
    Exp Neurol. 2016 Dec 23. pii: S0014-4886(16)30418.
    PubMed     Text format     Abstract available


    October 2016
  41. BECK MH, Haumesser JK, Kuhn J, Altschuler J, et al
    Short- and long-term dopamine depletion causes enhanced beta oscillations in the cortico-basal ganglia loop of parkinsonian rats.
    Exp Neurol. 2016;286:124-136.
    PubMed     Text format     Abstract available


    September 2016
  42. MULAS G, Espa E, Fenu S, Spiga S, et al
    Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Exp Neurol. 2016 Sep 30. pii: S0014-4886(16)30299.
    PubMed     Text format     Abstract available


  43. WU Q, Yang X, Zhang Y, Zhang L, et al
    Chronic mild stress accelerates the progression of Parkinson's disease in A53T alpha-synuclein transgenic mice.
    Exp Neurol. 2016;285.
    PubMed     Text format     Abstract available


    July 2016
  44. GEE LE, Walling I, Ramirez-Zamora A, Shin DS, et al
    Subthalamic deep brain stimulation alters neuronal firing in canonical pain nuclei in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.
    Exp Neurol. 2016;283.
    PubMed     Text format     Abstract available


    June 2016
  45. CONCANNON RM, Okine BN, Finn DP, Dowd E, et al
    Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease.
    Exp Neurol. 2016 Jun 14. pii: S0014-4886(16)30179.
    PubMed     Text format     Abstract available


    May 2016
  46. LI M, Zhou M, Wen P, Wang Q, et al
    The network of causal interactions for beta oscillations in the pedunculopontine nucleus, primary motor cortex, and subthalamic nucleus of walking parkinsonian rats.
    Exp Neurol. 2016 May 6. pii: S0014-4886(16)30122.
    PubMed     Text format     Abstract available


    April 2016
  47. SGROI S, Capper-Loup C, Paganetti P, Kaelin-Lang A, et al
    Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
    Exp Neurol. 2016 Apr 9. pii: S0014-4886(16)30066.
    PubMed     Text format     Abstract available


    March 2016
  48. MURALIDHARAN A, Jensen AL, Connolly A, Hendrix CM, et al
    Physiological changes in the pallidum in a progressive model of Parkinson's disease: Are oscillations enough?
    Exp Neurol. 2016 Mar 2. pii: S0014-4886(16)30046.
    PubMed     Text format     Abstract available


    February 2016
  49. LELOS MJ, Morgan RJ, Kelly CM, Torres EM, et al
    Amelioration of non-motor dysfunctions after transplantation of human dopamine neurons in a model of Parkinson's disease.
    Exp Neurol. 2016 Feb 3. pii: S0014-4886(16)30025.
    PubMed     Text format     Abstract available


    December 2015
  50. ANZAK A, Tan H, Pogosyan A, Khan S, et al
    Subcortical evoked activity and motor enhancement in Parkinson's disease.
    Exp Neurol. 2015 Dec 11. pii: S0014-4886(15)30131.
    PubMed     Text format     Abstract available


    November 2015
  51. BENSAID M, Michel PP, Clark SD, Hirsch EC, et al
    Role of pedunculopontine cholinergic neurons in the vulnerability of nigral dopaminergic neurons in Parkinson's disease.
    Exp Neurol. 2015 Nov 10. pii: S0014-4886(15)30118.
    PubMed     Text format     Abstract available


  52. SASAKI T, Liu K, Agari T, Yasuhara T, et al
    Anti-high mobility group box 1 antibody exerts neuroprotection in a rat model of Parkinson's disease.
    Exp Neurol. 2015 Nov 7. pii: S0014-4886(15)30117.
    PubMed     Text format     Abstract available


    October 2015
  53. HUANG Q, Du X, He X, Yu Q, et al
    JNK-mediated activation of ATF2 contributes to dopaminergic neurodegeneration in the MPTP mouse model of Parkinson's disease.
    Exp Neurol. 2015 Oct 26. pii: S0014-4886(15)30111.
    PubMed     Text format     Abstract available


  54. MARTIN CA, Myers KM, Chen A, Martin NT, et al
    Ziram, a pesticide associated with increased risk for Parkinson's disease, differentially affects the presynaptic function of aminergic and glutamatergic nerve terminals at the Drosophila neuromuscular junction.
    Exp Neurol. 2015 Oct 3. pii: S0014-4886(15)30099.
    PubMed     Text format     Abstract available


    August 2015
  55. MOUNSEY RB, Mustafa S, Robinson L, Ross RA, et al
    Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
    Exp Neurol. 2015 Aug 2. pii: S0014-4886(15)30058.
    PubMed     Text format     Abstract available


    May 2015
  56. YANG X, Zhao H, Shi H, Wang X, et al
    Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Exp Neurol. 2015 May 19. pii: S0014-4886(15)00154.
    PubMed     Text format     Abstract available


  57. SMITH RC, O'Bryan LM, Mitchell PJ, Leung D, et al
    Increased brain bio-distribution and chemical stability and decreased immunogenicity of an engineered variant of GDNF.
    Exp Neurol. 2015;267:165-76.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: